Niamh Coleman1, Vasiliki Michalarea1, Scheryll Alken1, Karim Rihawi1, Raquel Perez Lopez2, Nina Tunariu2, Ann Petruckevitch1, L R Molife1, Udai Banerji1, Johann S De Bono1, Liam Welsh3, Frank Saran3, Juanita Lopez4. 1. Drug Development Unit, The Royal Marsden Hospital Trust and Institute of Cancer Research, 15 Cotswold Road, Sutton, London, SM2 5NG, UK. 2. Radiology Department, The Royal Marsden Hospital Trust and Institute of Cancer Research, 15 Cotswold Road, Sutton, London, SM2 5NG, UK. 3. Neuro-oncology Department, The Royal Marsden Hospital Trust and Institute of Cancer Research, 15 Cotswold Road, Sutton, London, SM2 5NG, UK. 4. Drug Development Unit, The Royal Marsden Hospital Trust and Institute of Cancer Research, 15 Cotswold Road, Sutton, London, SM2 5NG, UK. Juanita.lopez@icr.ac.uk.
Abstract
BACKGROUND: Primary malignant brain tumours (PMBT) constitute less than 2% of all malignancies and carry a dismal prognosis. Treatment options at relapse are limited. First-in-human solid tumour studies have historically excluded patients with PMBT due to the poor prognosis, concomitant drug interactions and concerns regarding toxicities. METHODS: Retrospective data were collected on clinical and tumour characteristics of patients referred for consideration of Ph1 trials in the Royal Marsden Hospital between June 2004 and August 2016. Survival analyses were performed using the Kaplan-Meier method, Cox proportional hazards model. Chi squared test was used to measure bivariate associations between categorical variables. RESULTS: 100pts with advanced PMBT were referred. At initial consultation, patients had a median ECOG PS 1, median age 48 years (range 18-70); 69% were men, 76% had glioblastoma; 68% were on AEDs, 63% required steroid therapy; median number of prior treatments was two. Median OS for patients treated on a Ph1 trials was 9.3 months (95% CI 5.9-12.9) versus 5.3 months (95% CI 4.1-6.1) for patients that did not proceed with a Ph1 trial, p = 0.0094. Steroid use, poor PS, neutrophil-to-lymphocyte ratio and treatment on a Ph1 trial were shown to independently influence OS. CONCLUSIONS: We report a survival benefit for patients with PMBT treated on Ph1 trials. Toxicity and efficacy outcomes were comparable to the general Ph1 population. In the absence of an internationally recognized standard second line treatment for patients with recurrent PMBT, more Ph1 trials should allow enrolment of patients with refractory PMBT and Ph1 trial participation should be considered at an earlier stage.
BACKGROUND: Primary malignant brain tumours (PMBT) constitute less than 2% of all malignancies and carry a dismal prognosis. Treatment options at relapse are limited. First-in-human solid tumour studies have historically excluded patients with PMBT due to the poor prognosis, concomitant drug interactions and concerns regarding toxicities. METHODS: Retrospective data were collected on clinical and tumour characteristics of patients referred for consideration of Ph1 trials in the Royal Marsden Hospital between June 2004 and August 2016. Survival analyses were performed using the Kaplan-Meier method, Cox proportional hazards model. Chi squared test was used to measure bivariate associations between categorical variables. RESULTS: 100pts with advanced PMBT were referred. At initial consultation, patients had a median ECOG PS 1, median age 48 years (range 18-70); 69% were men, 76% had glioblastoma; 68% were on AEDs, 63% required steroid therapy; median number of prior treatments was two. Median OS for patients treated on a Ph1 trials was 9.3 months (95% CI 5.9-12.9) versus 5.3 months (95% CI 4.1-6.1) for patients that did not proceed with a Ph1 trial, p = 0.0094. Steroid use, poor PS, neutrophil-to-lymphocyte ratio and treatment on a Ph1 trial were shown to independently influence OS. CONCLUSIONS: We report a survival benefit for patients with PMBT treated on Ph1 trials. Toxicity and efficacy outcomes were comparable to the general Ph1 population. In the absence of an internationally recognized standard second line treatment for patients with recurrent PMBT, more Ph1 trials should allow enrolment of patients with refractory PMBT and Ph1 trial participation should be considered at an earlier stage.
Entities:
Keywords:
Drug development; Glioblastoma; High grade glioma; Malignant brain tumour; Phase I
Authors: L R Molife; S Alam; D Olmos; M Puglisi; K Shah; R Fehrmann; L Trani; A Tjokrowidjaja; J S de Bono; U Banerji; S B Kaye Journal: Ann Oncol Date: 2012-03-09 Impact factor: 32.976
Authors: Lola B Chambless; Scott L Parker; Laila Hassam-Malani; Matthew J McGirt; Reid C Thompson Journal: J Neurooncol Date: 2011-08-11 Impact factor: 4.130
Authors: Thomas G Roberts; Bernardo H Goulart; Lee Squitieri; Sarah C Stallings; Elkan F Halpern; Bruce A Chabner; G Scott Gazelle; Stan N Finkelstein; Jeffrey W Clark Journal: JAMA Date: 2004-11-03 Impact factor: 56.272
Authors: Wolfgang Wick; Vinay K Puduvalli; Marc C Chamberlain; Martin J van den Bent; Antoine F Carpentier; Lawrence M Cher; Warren Mason; Michael Weller; Shengyan Hong; Luna Musib; Astra M Liepa; Donald E Thornton; Howard A Fine Journal: J Clin Oncol Date: 2010-02-01 Impact factor: 44.544
Authors: Jigisha P Thakkar; Therese A Dolecek; Craig Horbinski; Quinn T Ostrom; Donita D Lightner; Jill S Barnholtz-Sloan; John L Villano Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-07-22 Impact factor: 4.254
Authors: Rachel L Derr; Xiaobu Ye; Melissa U Islas; Serena Desideri; Christopher D Saudek; Stuart A Grossman Journal: J Clin Oncol Date: 2009-01-12 Impact factor: 44.544